Madan Rebecca Pellett, Mesquita Pedro M M, Cheshenko Natalia, Jing Bingwen, Shende Vikas, Guzman Esmeralda, Heald Taylor, Keller Marla J, Regen Steven L, Shattock Robin J, Herold Betsy C
Department of Pediatrics, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA.
J Virol. 2007 Jul;81(14):7636-46. doi: 10.1128/JVI.02851-06. Epub 2007 May 9.
Molecular umbrella compounds may function as novel topical microbicides to prevent human immunodeficiency virus (HIV) and herpes simplex virus (HSV) infections. In a preliminary structure-activity investigation, one umbrella compound, designated Spm8CHAS, was identified which inhibited both HIV and HSV infections with no cellular toxicity. The objectives of the current studies were to define its spectrum of antiviral activity, characterize its mechanism of action, and explore the possibility of combining Spm8CHAS with HIV-specific reverse transcriptase inhibitors. Spm8CHAS inhibited infections by laboratory and clinical R5 and X4 clade B and clade C HIV strains in cell culture. Ectocervical tissue explants exposed to HIV-1(BaL) in the presence of Spm8CHAS were completely protected (50% inhibitory concentration [IC(50)], 13.6 microg/ml), and transfer of virus to target T cells via migratory cells was abolished (IC(50), 3.8 microg/ml). Spm8CHAS inhibited HSV-2 infection of epithelial cells 10,000-fold if present throughout the infection. Notably, adding Spm8CHAS to cultures following HSV entry significantly reduced viral infection, indicating that the drug also acts postentry. Subsequent studies indicated that Spm8CHAS blocks cell-to-cell spread of HSV. Confocal microscopy using a fluorescently labeled analog of Spm8CHAS demonstrated that this conjugate crosses the plasma cell membrane and is transported to the nucleus. Combinations of Spm8CHAS with UC-781 or 9-[R-2-(phosphonylmethoxy)propyl] adenine monohydrate in vitro exhibited additive anti-HIV activity with preserved anti-HSV activity. The abilities of Spm8CHAS to inhibit primary isolates of HIV, block HSV infection postentry, and cross cell membranes support the development of a combination microbicide containing Spm8CHAS with an HIV-specific reverse transcriptase inhibitor to prevent both HIV and HSV infections by multiple mechanisms.
分子伞状化合物可能作为新型局部杀菌剂来预防人类免疫缺陷病毒(HIV)和单纯疱疹病毒(HSV)感染。在一项初步的构效关系研究中,鉴定出一种名为Spm8CHAS的伞状化合物,它能抑制HIV和HSV感染且无细胞毒性。当前研究的目的是确定其抗病毒活性谱,阐明其作用机制,并探索将Spm8CHAS与HIV特异性逆转录酶抑制剂联合使用的可能性。Spm8CHAS在细胞培养中可抑制实验室和临床R5及X4亚型B和C的HIV毒株感染。在Spm8CHAS存在的情况下,暴露于HIV-1(BaL)的宫颈外植体受到完全保护(半数抑制浓度[IC(50)],13.6微克/毫升),并且通过迁移细胞将病毒传递至靶T细胞的过程被消除(IC(50),3.8微克/毫升)。如果在整个感染过程中都存在Spm8CHAS,它可将上皮细胞的HSV-2感染抑制10000倍。值得注意的是,在HSV进入细胞后向培养物中添加Spm8CHAS可显著降低病毒感染,这表明该药物在病毒进入后也有作用。后续研究表明Spm8CHAS可阻断HSV的细胞间传播。使用Spm8CHAS的荧光标记类似物进行的共聚焦显微镜检查表明,这种共轭物可穿过浆细胞膜并被转运至细胞核。Spm8CHAS与UC-781或9-[R-2-(膦酰甲氧基)丙基]腺嘌呤一水合物在体外联合使用时表现出相加的抗HIV活性,同时保留了抗HSV活性。Spm8CHAS抑制HIV原代分离株、阻断HSV感染后作用以及穿过细胞膜的能力支持开发一种包含Spm8CHAS与HIV特异性逆转录酶抑制剂的联合杀菌剂,通过多种机制预防HIV和HSV感染。